James F. White
Plus aucun poste en cours
Profil
James F.
White was the founder of CoLucid Pharmaceuticals, Inc. founded in 2005, where he held the title of President & Chief Executive Officer.
He previously worked as a Senior Toxicologist Officer at Eli Lilly & Co. and as a Senior Scientific Advisor at Hypnion, Inc. from 2001 to 2009.
Dr. White received his undergraduate, graduate, and doctorate degrees from Purdue University in 1975, 1977, and 1979, respectively.
Anciens postes connus de James F. White
| Sociétés | Poste | Fin |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| COLUCID PHARMACEUTICALS INC | Fondateur | - |
Hypnion, Inc.
 Hypnion, Inc. Miscellaneous Commercial ServicesCommercial Services Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA. | Directeur des opérations | - |
Formation de James F. White
| Purdue University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 2 |
|---|---|
Hypnion, Inc.
Hypnion, Inc. Miscellaneous Commercial ServicesCommercial Services Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA. | Commercial Services |
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
